Wong F L, Hamidah N H, Hawa A A, Nurul A N, Leong C F, Saw Fadilah, Ainoon O
Haematology Unit, Department of Pathology, Universiti Kebangsaan Malaysia Medical Centre, Universiti Kebangsaan Malaysia, Kuala Lumpur.
Malays J Pathol. 2011 Dec;33(2):107-12.
Molecular pathogenesis of chronic myeloid leukemia (CML) is well established and molecular monitoring for patients with CML has become an important practice in the management of patients on imatinib therapy. In the present study, we report the use of RQ-PCR method for detection of BCR-ABL fusion gene for our CML cases. We performed a two-step RQ-PCR on bone marrow aspirates or peripheral blood of 37 CML patients. Quantitative expression of BCR-ABL fusion gene was carried out relative to the expression of a housekeeping gene as endogenous control to compensate for uneven cell numbers, RNA quality, or variations in reverse transcription efficiencies. Twenty-four of these patients were pre-treated with hydroxyurea or alpha interferon prior to the imatinib therapy. Their BCR-ABL fusion gene levels were monitored for 18 months. All samples processed were evaluable. The PCR amplification efficiency of the ABL gene is 90.5% (0.2158) and the BCR-ABL gene, 93.4% (0.1573).
慢性髓性白血病（CML）的分子发病机制已得到充分证实，对CML患者进行分子监测已成为伊马替尼治疗患者管理中的一项重要实践。在本研究中，我们报告了使用RQ-PCR方法检测我们的CML病例中的BCR-ABL融合基因。我们对37例CML患者的骨髓穿刺液或外周血进行了两步RQ-PCR。相对于作为内源性对照的管家基因的表达，进行BCR-ABL融合基因的定量表达，以补偿细胞数量不均、RNA质量或逆转录效率的变化。这些患者中有24例在伊马替尼治疗前接受过羟基脲或α干扰素预处理。对他们的BCR-ABL融合基因水平进行了18个月的监测。所有处理的样本均可评估。ABL基因的PCR扩增效率为90.5%（0.2158），BCR-ABL基因的PCR扩增效率为93.4%（0.1573）。
